Drug Patents Expiring in 2038

1. List of Adhansia Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10722473 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Nov, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Feb 27, 2022
M Jun 28, 2024

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 27 February, 2019

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

2. List of Adlarity drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835499 CORIUM Systems and methods for long term transdermal administration
May, 2038

(15 years from now)

US10966936 CORIUM Systems comprising a composite backing and methods for long term transdermal administration
Aug, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 11, 2025

Drugs and Companies using DONEPEZIL HYDROCHLORIDE ingredient

Market Authorisation Date: 11 March, 2022

Treatment: A method of transdermal delivery of donepezil for treating mild, moderate and severe dementia of the alzheimer's type

Dosage: SYSTEM;TRANSDERMAL

More Information on Dosage

3. List of Airduo Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11351317 TEVA PHARM Drug delivery device with electronics
Feb, 2038

(15 years from now)

US11351317

(Pediatric)

TEVA PHARM Drug delivery device with electronics
Aug, 2038

(15 years from now)

US11357935 TEVA PHARM Drug delivery device with electronics
Sep, 2038

(15 years from now)

US11000653 TEVA PHARM Inhaler
Dec, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
M Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

4. List of Altreno drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10653656 DOW PHARM Topical pharmaceutical compositions for treating skin conditions
Aug, 2038

(15 years from now)

US11324710 DOW PHARM Topical pharmaceutical compositions for treating skin conditions
Aug, 2038

(15 years from now)

Drugs and Companies using TRETINOIN ingredient

Market Authorisation Date: 23 August, 2018

Treatment: Topical treatment of acne vulgaris in patients 9 years of age and older

Dosage: LOTION;TOPICAL

More Information on Dosage

5. List of Arazlo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11311482 BAUSCH Topical compositions and methods for treating skin diseases
May, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Dec 18, 2022

Drugs and Companies using TAZAROTENE ingredient

Market Authorisation Date: 18 December, 2019

Treatment: Topical treatment of acne vulgaris in patients 9 years of age and older

Dosage: LOTION;TOPICAL

How can I launch a generic of ARAZLO before it's patent expiration?
More Information on Dosage

6. List of Armonair Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11351317 TEVA PHARM Drug delivery device with electronics
Feb, 2038

(15 years from now)

US11351317

(Pediatric)

TEVA PHARM Drug delivery device with electronics
Aug, 2038

(15 years from now)

US11357935 TEVA PHARM Drug delivery device with electronics
Sep, 2038

(15 years from now)

US11000653 TEVA PHARM Inhaler
Dec, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 9, 2024
New Strength (NS) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

7. List of Aspruzyo Sprinkle drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11510878 SPIL NA
Jan, 2038

(14 years from now)

US10898444 SPIL Extended release multiparticulates of ranolazine
Jan, 2038

(14 years from now)

Drugs and Companies using RANOLAZINE ingredient

Market Authorisation Date: 28 February, 2022

Treatment: NA

Dosage: GRANULES, EXTENDED RELEASE;ORAL

More Information on Dosage

8. List of Austedo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11179386 TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use
Mar, 2038

(15 years from now)

US11179386

(Pediatric)

TEVA BRANDED PHARM Analogs of deutetrabenazine, their preparation and use
Sep, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 3, 2024
New Chemical Entity Exclusivity (NCE) Apr 3, 2022
M Jun 24, 2024
Pediatric Exclusivity (PED) Oct 3, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

NCE-1 date: October, 2023

Market Authorisation Date: 03 April, 2017

Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea

Dosage: TABLET;ORAL

How can I launch a generic of AUSTEDO before it's patent expiration?
More Information on Dosage

9. List of Balversa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11077106 JANSSEN BIOTECH Cancer treatment
Feb, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 12, 2024

Drugs and Companies using ERDAFITINIB ingredient

NCE-1 date: April, 2023

Market Authorisation Date: 12 April, 2019

Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible fgfr3 or fgfr2 genetic alterations, and progressed during or following prior platinum-containing chemotherapy, with dosing based on serum phosphate levels

Dosage: TABLET;ORAL

More Information on Dosage

10. List of Baqsimi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10894133 ELI LILLY AND CO Device for dispensing a fluid product
Jan, 2038

(14 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Jul 24, 2022

Drugs and Companies using GLUCAGON ingredient

Market Authorisation Date: 24 July, 2019

Treatment: NA

Dosage: POWDER;NASAL

More Information on Dosage

11. List of Barhemsys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11357753 ACACIA Rescue treatment of post operative nausea and vomiting
Feb, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 26, 2025

Drugs and Companies using AMISULPRIDE ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 26 February, 2020

Treatment: Treatment of post-operative nausea and vomiting

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

12. List of Breztri Aerosphere drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11331442 ASTRAZENECA AB Drug delivery systems and related methods
May, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Combination (NC) Jul 23, 2023

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 23 July, 2020

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

13. List of Cerdelga drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888544 GENZYME CORP Methods for treating Gaucher disease
Dec, 2038

(15 years from now)

Drugs and Companies using ELIGLUSTAT TARTRATE ingredient

Market Authorisation Date: 19 August, 2014

Treatment: Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive metabolizers with moderate to severe renal impairment; Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive metabolizers with mild hepatic impairment and are concurrently taking a strong or moderate cyp3a inhibitor

Dosage: CAPSULE;ORAL

How can I launch a generic of CERDELGA before it's patent expiration?
More Information on Dosage

14. List of Consensi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350171 PURPLE BIOTECH Celecoxib and amlodipine formulation and method of making the same
Jun, 2038

(15 years from now)

US10925835 PURPLE BIOTECH Celecoxib and amlodipine formulation and method of making the same
Jun, 2038

(15 years from now)

US10945960 PURPLE BIOTECH Celecoxib and amlodipine formulation and method of making the same
Jun, 2038

(15 years from now)

Drugs and Companies using AMLODIPINE BESYLATE; CELECOXIB ingredient

Market Authorisation Date: 31 May, 2018

Treatment: Treatment of adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate

Dosage: TABLET;ORAL

How can I launch a generic of CONSENSI before it's patent expiration?
More Information on Dosage

15. List of Cotempla Xr-odt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11166947 NEOS THERAPS INC Effective dosing of a child for the treatment of ADHD with methylphenidate
Jan, 2038

(14 years from now)

Drugs and Companies using METHYLPHENIDATE ingredient

Market Authorisation Date: 19 June, 2017

Treatment: Treatment of attention deficit hyperactivity disorder (adhd) in pediatric patients

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

How can I launch a generic of COTEMPLA XR-ODT before it's patent expiration?
More Information on Dosage

16. List of Cysview Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11235168 PHOTOCURE ASA Method of photodynamic therapy (PDT) for bladder cancer
Jan, 2038

(14 years from now)

Drugs and Companies using HEXAMINOLEVULINATE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 May, 2010

Treatment: Detection of carcinoma in the bladder by photodynamic cystoscopy

Dosage: FOR SOLUTION;INTRAVESICAL

More Information on Dosage

17. List of Empaveli drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11040107 APELLIS PHARMS Dosing regimens and related compositions and methods
Apr, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 14, 2026
Orphan Drug Exclusivity (ODE) May 14, 2028

Drugs and Companies using PEGCETACOPLAN ingredient

NCE-1 date: May, 2025

Market Authorisation Date: 14 May, 2021

Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan; Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan every three days; Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan twice weekly

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

18. List of Erleada drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10702508 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
Apr, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 14, 2023
New Indication (I) Sep 17, 2022

Drugs and Companies using APALUTAMIDE ingredient

NCE-1 date: February, 2022

Market Authorisation Date: 14 February, 2018

Treatment: Treatment in combination with androgen deprivation therapy of non-metastatic, castration-resistant prostate cancer (nmcrpc) that improves metastasis free survival

Dosage: TABLET;ORAL

How can I launch a generic of ERLEADA before it's patent expiration?
More Information on Dosage

19. List of Ferriprox drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10940116 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(15 years from now)

US10940115 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(15 years from now)

US11458103 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(15 years from now)

US11357731 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(15 years from now)

US10780055 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Apr 30, 2024

Drugs and Companies using DEFERIPRONE ingredient

Market Authorisation Date: 19 May, 2020

Treatment: Method of treating transfusional iron overload

Dosage: TABLET;ORAL

More Information on Dosage

20. List of Fintepla drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11040018

(Pediatric)

ZOGENIX INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Feb, 2038

(15 years from now)

US10603290

(Pediatric)

ZOGENIX INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Feb, 2038

(15 years from now)

US11406606

(Pediatric)

ZOGENIX INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Feb, 2038

(15 years from now)

US10452815 ZOGENIX INC Control system for control of distribution of medication
Jun, 2038

(15 years from now)

US10452815

(Pediatric)

ZOGENIX INC Control system for control of distribution of medication
Dec, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 25, 2027
New Product (NP) Jun 25, 2023
New Indication (I) Mar 25, 2025
Pediatric Exclusivity (PED) Dec 25, 2027

Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 25 June, 2020

Treatment: Use of cardiac monitoring and restricted distribution of fenfluramine to mitigate risk of cardiovascular toxicity in the treatment of seizures associated with dravet syndrome

Dosage: SOLUTION;ORAL

How can I launch a generic of FINTEPLA before it's patent expiration?
More Information on Dosage

21. List of Galafold drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11357765 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11304940 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11426396 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11357764 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11376244 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458128 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10806727 AMICUS THERAP US Methods of treating fabry patients having renal impairment
May, 2038

(15 years from now)

US10799491 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10792279 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10792278 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10874656 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10874655 AMICUS THERAP US Methods of treating fabry patients having renal impairment
May, 2038

(15 years from now)

US10874657 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10857142 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10849889 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10849890 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10857141 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10471053 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US10251873 AMICUS THERAP US Methods of treating fabry patients having renal impairment
May, 2038

(15 years from now)

US11357761 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11357762 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11357763 AMICUS THERAP US Methods of treating fabry patients having renal impairment
May, 2038

(15 years from now)

US11389437 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11389436 AMICUS THERAP US Methods of treating fabry patients having renal impairment
May, 2038

(15 years from now)

US11278538 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11278537 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11278536 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11278539 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

US11278540 AMICUS THERAP US Methods of treating Fabry patients having renal impairment
May, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 10, 2023
Orphan Drug Exclusivity (ODE) Aug 10, 2025

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

NCE-1 date: August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: The treatment of fabry patients

Dosage: CAPSULE;ORAL

How can I launch a generic of GALAFOLD before it's patent expiration?
More Information on Dosage

22. List of Gocovri drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11065213 ADAMAS PHARMA Amantadine compositions and preparations thereof
Aug, 2038

(15 years from now)

US11077073 ADAMAS PHARMA Methods of using amantadine compositions
Aug, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 24, 2024

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 August, 2017

Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Decreasing off time in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of GOCOVRI before it's patent expiration?
More Information on Dosage

23. List of Iheezo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10792271 SINTETICA SA Topical formulations of chloroprocaine and methods of using same
Sep, 2038

(15 years from now)

Drugs and Companies using CHLOROPROCAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 27 September, 2022

Treatment: Method of inducing ocular anesthesia

Dosage: GEL;OPHTHALMIC

More Information on Dosage

24. List of Ingrezza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11311532 NEUROCRINE High dosage valbenazine formulation and compositions, methods, and kits related thereto
Sep, 2038

(15 years from now)

US11026939 NEUROCRINE High dosage valbenazine formulation and compositions, methods, and kits related thereto
Sep, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 11, 2022

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

NCE-1 date: April, 2021

Market Authorisation Date: 11 April, 2017

Treatment: Treatment of tardive dyskinesia

Dosage: CAPSULE;ORAL

How can I launch a generic of INGREZZA before it's patent expiration?
More Information on Dosage

25. List of Klisyri drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10669236 ALMIRALL Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
Sep, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11497750 ALMIRALL Methods of treating and/or preventing actinic keratosis
Mar, 2038

(15 years from now)

US10617693 ALMIRALL Methods of treating and/or preventing actinic keratosis
Mar, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 14, 2025

Drugs and Companies using TIRBANIBULIN ingredient

NCE-1 date: December, 2024

Market Authorisation Date: 14 December, 2020

Treatment: Topical treatment of actinic keratosis of the face or scalp

Dosage: OINTMENT;TOPICAL

More Information on Dosage

26. List of Korlym drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10231983 CORCEPT THERAP Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
Aug, 2038

(15 years from now)

US10780097 CORCEPT THERAP Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
Aug, 2038

(15 years from now)

US10314850 CORCEPT THERAP Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
Aug, 2038

(15 years from now)

Drugs and Companies using MIFEPRISTONE ingredient

Market Authorisation Date: 17 February, 2012

Treatment: Treating cushing's syndrome

Dosage: TABLET;ORAL

How can I launch a generic of KORLYM before it's patent expiration?
More Information on Dosage

27. List of Levolet drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10406108 GENUS LIFESCIENCES Thyroid hormone oral dosage forms and methods of using the same
Mar, 2038

(15 years from now)

US10231931 GENUS LIFESCIENCES Thyroid hormone oral dosage forms and methods of using the same
Mar, 2038

(15 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 06 June, 2003

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

28. List of Levulan drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11135293 DUSA Methods for photodynamic therapy
Jan, 2038

(14 years from now)

US10357567 DUSA Methods for photodynamic therapy
Jan, 2038

(14 years from now)

US11077192 DUSA Methods for photodynamic therapy
Jan, 2038

(14 years from now)

Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient

Market Authorisation Date: 03 December, 1999

Treatment: Treatment of actinic keratoses of upper extremities by photodynamic therapy

Dosage: SOLUTION;TOPICAL

More Information on Dosage

29. List of Lorbrena drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11299500 PFIZER Crystalline form of lorlatinib free base hydrate
Oct, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 2, 2023
Orphan Drug Exclusivity (ODE) Mar 3, 2028
New Indication (I) Mar 3, 2024

Drugs and Companies using LORLATINIB ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 02 November, 2018

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

30. List of Lumakras drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10519146 AMGEN INC KRAS G12C inhibitors and methods of using the same
May, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 28, 2026
Orphan Drug Exclusivity (ODE) May 28, 2028

Drugs and Companies using SOTORASIB ingredient

NCE-1 date: May, 2025

Market Authorisation Date: 28 May, 2021

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

31. List of Lumason drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10335502 BRACCO Freeze-dried formulation for gas-filled microvesicles
Jul, 2038

(15 years from now)

US10232061 BRACCO Freeze-dried formulation for gas-filled microvesicles
Jul, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Nov 13, 2022

Drugs and Companies using SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES ingredient

Market Authorisation Date: 15 October, 2014

Treatment: NA

Dosage: FOR SUSPENSION;INTRAVENOUS

More Information on Dosage

32. List of Lutathera drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596278 AAA USA INC Stable, concentrated radionuclide complex solutions
Jul, 2038

(15 years from now)

US10596276 AAA USA INC Stable, concentrated radionuclide complex solutions
Jul, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 26, 2023
Orphan Drug Exclusivity (ODE) Jan 26, 2025

Drugs and Companies using LUTETIUM DOTATATE LU-177 ingredient

NCE-1 date: January, 2022

Market Authorisation Date: 26 January, 2018

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

33. List of Mavenclad drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10849919 EMD SERONO INC Cladribine regimen for treating progressive forms of multiple sclerosis
Nov, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 29, 2022

Drugs and Companies using CLADRIBINE ingredient

Market Authorisation Date: 29 March, 2019

Treatment: Treating non-early spms by administering oral cladribine at a fixed dose per patient, per body weight and per treatment year, which fixed dose is 1.75 +/- 0.2 mg/kg, to be administered within months 1 and 2 in each of 2 adjacent treatment years

Dosage: TABLET;ORAL

How can I launch a generic of MAVENCLAD before it's patent expiration?
More Information on Dosage

34. List of Midazolam In 0.9% Sodium Chloride drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10966990 INFORLIFE Midazolam in flexible bags
Jun, 2038

(15 years from now)

Drugs and Companies using MIDAZOLAM ingredient

Market Authorisation Date: 22 March, 2021

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of MIDAZOLAM IN 0.9% SODIUM CHLORIDE before it's patent expiration?
More Information on Dosage

35. List of Norepinephrine Bitartrate In 0.9% Sodium Chloride drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10568850 NEVAKAR INJECTABLES Norepinephrine compositions and methods therefor
Jan, 2038

(14 years from now)

US11413259 NEVAKAR INJECTABLES Norepinephrine compositions and methods therefor
Jan, 2038

(14 years from now)

US10420735 NEVAKAR INJECTABLES Norepinephrine compositions and methods therefor
Jan, 2038

(14 years from now)

US10226436 NEVAKAR INJECTABLES Norepinephrine compositions and methods therefor
Jan, 2038

(14 years from now)

US10159657 NEVAKAR INJECTABLES Norepinephrine compositions and methods therefor
Jan, 2038

(14 years from now)

Drugs and Companies using NOREPINEPHRINE BITARTRATE ingredient

Market Authorisation Date: 06 October, 2022

Treatment: Indicated to raise blood pressure in adult patients with severe, acute hypotension

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

36. List of Nubeqa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11168058 BAYER HEALTHCARE Manufacture of a crystalline pharmaceutical product
Feb, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 30, 2024
New Indication (I) Aug 5, 2025

Drugs and Companies using DAROLUTAMIDE ingredient

NCE-1 date: July, 2023

Market Authorisation Date: 30 July, 2019

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

37. List of Nuplazid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10849891 ACADIA PHARMS INC Formulations of pimavanserin
Aug, 2038

(15 years from now)

US10449185 ACADIA PHARMS INC Formulations of pimavanserin
Aug, 2038

(15 years from now)

US10646480 ACADIA PHARMS INC Formulations of pimavanserin
Aug, 2038

(15 years from now)

US11452721 ACADIA PHARMS INC Formulations of pimavanserin
Aug, 2038

(15 years from now)

Drugs and Companies using PIMAVANSERIN TARTRATE ingredient

Market Authorisation Date: 28 June, 2018

Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis

Dosage: CAPSULE;ORAL

How can I launch a generic of NUPLAZID before it's patent expiration?
More Information on Dosage

38. List of Nymalize drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10342787 AZURITY Non-aqueous liquid nimodipine compositions
Apr, 2038

(15 years from now)

US11517563 AZURITY NA
Apr, 2038

(15 years from now)

US11413277 AZURITY Non-aqueous liquid nimodipine compositions
Apr, 2038

(15 years from now)

US11207306 AZURITY Non-aqueous liquid nimodipine compositions
Apr, 2038

(15 years from now)

US10576070 AZURITY Non-aqueous liquid nimodipine compositions
Apr, 2038

(15 years from now)

Drugs and Companies using NIMODIPINE ingredient

Market Authorisation Date: 10 May, 2013

Treatment: A method for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (sah) from ruptured intracranial berry aneurysms

Dosage: SOLUTION;ORAL

How can I launch a generic of NYMALIZE before it's patent expiration?
More Information on Dosage

39. List of Osmolex Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10500172 ADAMAS PHARMA Composition and method for treating neurological disease
Feb, 2038

(15 years from now)

US10213394 ADAMAS PHARMA Composition and method for treating neurological disease
Feb, 2038

(15 years from now)

US10213393 ADAMAS PHARMA Composition and method for treating neurological disease
Feb, 2038

(15 years from now)

US10512617 ADAMAS PHARMA Composition and method for treating neurological disease
Feb, 2038

(15 years from now)

US10500170 ADAMAS PHARMA Composition and method for treating neurological disease
Feb, 2038

(15 years from now)

US10500171 ADAMAS PHARMA Composition and method for treating neurological disease
Feb, 2038

(15 years from now)

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 February, 2018

Treatment: Treatment of drug-induced extrapyramidal reaction in adult patients; A process for treating a patient suffering from parkinson's syndrome and in need of treatment

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

40. List of Otiprio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11246863 ALK ABELLO Ciprofloxacin otic composition and kits and method for using same
Nov, 2038

(15 years from now)

Drugs and Companies using CIPROFLOXACIN ingredient

Market Authorisation Date: 10 December, 2015

Treatment: NA

Dosage: INJECTABLE, SUSPENSION;OTIC

More Information on Dosage

41. List of Oxlumo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11261447 ALNYLAM PHARMS INC Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
Nov, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 23, 2027
New Chemical Entity Exclusivity (NCE) Nov 23, 2025
New Indication (I) Oct 6, 2025

Drugs and Companies using LUMASIRAN SODIUM ingredient

NCE-1 date: November, 2024

Market Authorisation Date: 23 November, 2020

Treatment: Treatment of primary hyperoxaluria type 1 (ph1)

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

42. List of Pedmark drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596190 FENNEC PHARMS INC Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy
Jan, 2038

(14 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Sep 20, 2025

Drugs and Companies using SODIUM THIOSULFATE ingredient

Market Authorisation Date: 20 September, 2022

Treatment: A method of reducing ototoxicity in a human pediatric patient about 5 years of age or under with localized medulloblastoma comprising administering sodium thiosulfate about six hours after administration of cisplatin

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of PEDMARK before it's patent expiration?
More Information on Dosage

43. List of Proair Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11351317 TEVA BRANDED PHARM Drug delivery device with electronics
Feb, 2038

(15 years from now)

US11357935 TEVA BRANDED PHARM Drug delivery device with electronics
Sep, 2038

(15 years from now)

US11000653 TEVA BRANDED PHARM Inhaler
Dec, 2038

(15 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 31 March, 2015

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

44. List of Pyrukynd drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11254652 AGIOS PHARMS INC Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
Nov, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11234976 AGIOS PHARMS INC Methods of using pyruvate kinase activators
Oct, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 17, 2027

Drugs and Companies using MITAPIVAT SULFATE ingredient

NCE-1 date: February, 2026

Market Authorisation Date: 17 February, 2022

Treatment: Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency by administering a daily dose of 10mg to 100mg

Dosage: TABLET;ORAL

More Information on Dosage

45. List of Qvar Redihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11395888 NORTON WATERFORD Inhalers and related methods
Jan, 2038

(14 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 03 August, 2017

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

46. List of Retevmo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10584124 LOXO ONCOLOGY INC Crystalline forms
Oct, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10786489 LOXO ONCOLOGY INC Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile
Oct, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 8, 2025
Orphan Drug Exclusivity (ODE) May 8, 2027

Drugs and Companies using SELPERCATINIB ingredient

NCE-1 date: May, 2024

Market Authorisation Date: 08 May, 2020

Treatment: Treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is papillary thyroid cancer; The treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy; Treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is recurrent thyroid cancer; Treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is medullary thyroid cancer; The treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer (nsclc); Treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is differentiated thyroid cancer; Treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive refractory differentiated thyroid cancer who require systemic therapy and are radioactive iodine-refractory; Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine refractory (if radioactive iodine is appropriate); Treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer; Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy

Dosage: CAPSULE;ORAL

More Information on Dosage

47. List of Rozlytrek drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11253515 GENENTECH INC Pharmaceutical compositions and dosage forms
Jul, 2038

(15 years from now)

US10398693 GENENTECH INC Pharmaceutical compositions and dosage forms
Jul, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 15, 2026
New Chemical Entity Exclusivity (NCE) Aug 15, 2024

Drugs and Companies using ENTRECTINIB ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 15 August, 2019

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

48. List of Sincalide drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11318100 MAIA PHARMS INC Storage stable sincalide formulations
Apr, 2038

(15 years from now)

US11110063 MAIA PHARMS INC Storage stable sincalide formulations
Apr, 2038

(15 years from now)

Drugs and Companies using SINCALIDE ingredient

Market Authorisation Date: 22 November, 2022

Treatment: Accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract; Stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis; Stimulate pancreatic secretion in combination with secretin prior to obtaining a duodenal aspirate for analysis; Stimulate gallbladder contraction. as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis; Diagnosis of gall bladder disorders or other diagnostic imaging by stimulating gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis; Diagnosis of pancreatic disorders by stimulating pancreatic secretion in combination with secretin prior to obtajning a duodenal aspirate for analysis; Diagnostic imaging by accelerating the tran it ofa barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

49. List of Sotalol Hydrochloride drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10512620 ALTATHERA PHARMS LLC Method of initiating and escalating sotalol hydrochloride dosing
Aug, 2038

(15 years from now)

Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient

Market Authorisation Date: 02 July, 2009

Treatment: Dosing regimen for intravenous sotalol for administration in a facility that can provide continuous electrocardiographic monitoring and cardiac resuscitation.

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

50. List of Sublocade drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10646484 INDIVIOR INC Methods to treat opioid use disorder
Jun, 2038

(15 years from now)

Drugs and Companies using BUPRENORPHINE ingredient

Market Authorisation Date: 30 November, 2017

Treatment: Treatment of moderate to severe opioid use disorder

Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

51. List of Sunosi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10912754 JAZZ Methods and compositions for treating excessive sleepiness
Jun, 2038

(15 years from now)

US10959976 JAZZ Methods and compositions for treating excessive sleepiness
Jun, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: Treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in an adult through a dosing regimen that includes oral administration of 75 mg once daily for at least 3 days followed by 150 mg once daily; To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa) with a dosing regimen that includes a dose of 75 mg once daily for at least 3 days followed by 150 mg once daily

Dosage: TABLET;ORAL

More Information on Dosage

52. List of Symtuza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10786518 JANSSEN PRODS Compositions and methods of treating HIV
Jul, 2038

(15 years from now)

Drugs and Companies using COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 17 July, 2018

Treatment: Treatment of hiv-1 infection in adult or pediatric patients (>=40 kg) with <50 copies/ml hiv-1 rna after >= 6 months on prior antiretroviral regimen and no known darunavir or tenofovir resistance-associated substitutions

Dosage: TABLET;ORAL

How can I launch a generic of SYMTUZA before it's patent expiration?
More Information on Dosage

53. List of Tadliq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11382917 CMP DEV LLC Liquid oral formulations for tadalafil
Dec, 2038

(15 years from now)

Drugs and Companies using TADALAFIL ingredient

Market Authorisation Date: 17 June, 2022

Treatment: Tadliq is indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability

Dosage: SUSPENSION;ORAL

More Information on Dosage

54. List of Thiola Ec drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458104 MISSION PHARMACAL CO NA
Nov, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 28, 2026

Drugs and Companies using TIOPRONIN ingredient

Market Authorisation Date: 28 June, 2019

Treatment: A method of treating cystinuria by orally administering tiopronin with food to prevent cystine stone formation in adults and pediatric patients with severe homozygous cystinuria

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of THIOLA EC before it's patent expiration?
More Information on Dosage

55. List of Turalio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10435404 DAIICHI SANKYO INC Formulations of a compound modulating kinases
Jul, 2038

(15 years from now)

US10941142 DAIICHI SANKYO INC Formulations of a compound modulating kinases
Jul, 2038

(15 years from now)

US10961240 DAIICHI SANKYO INC Formulations of a compound modulating kinases
Jul, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 2, 2024
Orphan Drug Exclusivity (ODE) Aug 2, 2026

Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 02 August, 2019

Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery

Dosage: CAPSULE;ORAL

More Information on Dosage

56. List of Twyneo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10420743 GALDERMA LABS LP Methods and compositions for the treatment of acne
Jul, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Combination (NC) Jul 26, 2024

Drugs and Companies using BENZOYL PEROXIDE; TRETINOIN ingredient

Market Authorisation Date: 26 July, 2021

Treatment: Topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older

Dosage: CREAM;TOPICAL

More Information on Dosage

57. List of Tymlos drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10996208 RADIUS HEALTH INC Abaloparatide formulations and methods of testing, storing, modifying, and using same
Apr, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 28, 2022
M Sep 20, 2024

Drugs and Companies using ABALOPARATIDE ingredient

NCE-1 date: April, 2021

Market Authorisation Date: 28 April, 2017

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of TYMLOS before it's patent expiration?
More Information on Dosage

58. List of Veklury drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10675296 GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jul, 2038

(15 years from now)

US11266681 GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jul, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 22, 2025
New Patient Population (NPP) Apr 25, 2025
New Dosing Schedule (D) Jan 21, 2025

Drugs and Companies using REMDESIVIR ingredient

NCE-1 date: October, 2024

Market Authorisation Date: 22 October, 2020

Treatment: Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 12 years of age and 40 kg) requiring hospitalization; Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 12 years of age and 40 kg)

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

More Information on Dosage

59. List of Vtama drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10647649 DERMAVANT SCI Process for preparing tapinarof
Nov, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 23, 2027

Drugs and Companies using TAPINAROF ingredient

NCE-1 date: May, 2026

Market Authorisation Date: 23 May, 2022

Treatment: NA

Dosage: CREAM;TOPICAL

More Information on Dosage

60. List of Wegovy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888605 NOVO GLP-1 compositions and uses thereof
Aug, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 5, 2022
New Product (NP) Jun 4, 2024

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 04 June, 2021

Treatment: Method for weight management

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

61. List of Xofluza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11261198 GENENTECH INC Process for preparing substituted polycyclic pyridone derivative and crystal thereof
Sep, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Oct 16, 2022
New Chemical Entity Exclusivity (NCE) Oct 24, 2023

Drugs and Companies using BALOXAVIR MARBOXIL ingredient

NCE-1 date: October, 2022

Market Authorisation Date: 24 October, 2018

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of XOFLUZA before it's patent expiration?
More Information on Dosage

62. List of Xyosted (autoinjector) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10646495 ANTARES PHARMA INC Testosterone ester triglyceride formulations
Aug, 2038

(15 years from now)

Drugs and Companies using TESTOSTERONE ENANTHATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

63. List of Zejula drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11091459 GLAXOSMITHKLINE Niraparib compositions
Mar, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 29, 2027
New Chemical Entity Exclusivity (NCE) Mar 27, 2022
New Indication (I) Apr 29, 2023

Drugs and Companies using NIRAPARIB TOSYLATE ingredient

NCE-1 date: March, 2021

Market Authorisation Date: 27 March, 2017

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

64. List of Zonisade drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11529333 AZURITY Oral pharmaceutical composition comprising zonisamide and process of preparation thereof
Aug, 2038

(15 years from now)

US11478456 AZURITY NA
Aug, 2038

(15 years from now)

Drugs and Companies using ZONISAMIDE ingredient

Market Authorisation Date: 15 July, 2022

Treatment: A method of treating seizures

Dosage: SUSPENSION;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

List of large molecules

1. List of Eylea large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US10918754 REGENERON PHARMACEUTICALS, INC. Sterilisation method
Mar, 2038

(15 years from now)

US10905786 REGENERON PHARMACEUTICALS, INC. Sterilisation method
Mar, 2038

(15 years from now)

Ingredients: AFLIBERCEPT

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in